EAGLE PHARMACEUTICALS, INC.

EAGLE PHARMACEUTICALS, INC. insiders are currently net sellers of EGRX stock, showing bearish sentiment over the past 90 days. Total sales of $141.9M outpace purchases of $16.7M, creating a net outflow of $125.2M.

EAGLE PHARMACEUTICALS, INC. has 21 active insiders who have filed SEC Form 4 transactions in the past 90 days. Associates IV Llc Proquest (Executive) leads with 38 transactions totaling $46.9M. Scott Tarriff (Executive) follows with 76 transactions worth $30.4M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. EAGLE PHARMACEUTICALS, INC.'s current score of 11/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Feb 28, 2024, when Tarriff Scott (Executive) disposed of 2,119 shares at $6.27 per share for $13.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, EGRX insider trading sentiment is currently bearish with an Alignment Score of 11/100. The negative net flow of $125.2M shows more selling than buying. However, 10% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like EAGLE PHARMACEUTICALS, INC.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At EGRX, we track all Form 4 filings—currently showing 339 transactions from 21 insiders over 90 days.

A 10b5-1 plan allows EAGLE PHARMACEUTICALS, INC. executives to pre-schedule stock sales when they don't possess material non-public information. At EGRX, approximately 10% of recent transactions are 10b5-1 trades. The remaining 90% are discretionary trades, which may carry more informational value.

You can monitor EAGLE PHARMACEUTICALS, INC. (EGRX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 21 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. EAGLE PHARMACEUTICALS, INC.'s current score of 11/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $16.7M in purchases versus $141.9M in sales over 90 days, resulting in a net flow of -$125.2M.

SEC Form 4 filings are mandatory reports that EAGLE PHARMACEUTICALS, INC. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At EGRX, the most common type is "F" with 25 occurrences. The most recent Form 4 was filed on Feb 28, 2024 by Tarriff Scott.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At EAGLE PHARMACEUTICALS, INC., approximately 10% of recent transactions are executed under 10b5-1 plans, while 90% appear to be discretionary trades. The low percentage means most insider activity at EGRX represents discretionary decisions with more informational value.